Our platform provides comprehensive in vitro testing solutions for key co-inhibitory pathways, covering core targets including PD-1/PD-L1&L2, TIGIT/CD155, CTLA4, and LAG3, along with their common combinations. Utilizing standardized reporter cells and binding assays, we support activity evaluation, mechanism investigation, and drug screening for both single-target and dual immune checkpoint inhibitors, facilitating efficient development in cancer immunotherapy.
